Oct 7 (Reuters) – Soligenix Inc: * SOLIGENIX ACHIEVES IMPORTANT SAFETY MILESTONE IN ITS CONFIRMATORY PHASE 3 CLINICAL TRIAL OF HYBRYTE™ FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA * SOLIGENIX INC – FLASH2 STUDY INTERIM EFFICACY ANALYSIS TARGETED FOR 1H2026 * SOLIGENIX INC – ENROLLMENT UPDATE REMAINS ON TRACK FOR 4Q2025 Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)